TrialEuropean journal of nuclear medicine and molecular imaging2014

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.

Samer Ezziddin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.